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Abstract
Hadrontherapy is a form of external radiation therapy, which uses beams of
charged particles such as carbon ions. Compared to conventional radiotherapy
with photons, the main advantage of carbon ion therapy is the precise dose
localization along with an increased biological effectiveness. The first results
obtained from prostate cancer patients treated with carbon ion therapy showed
good local tumor control and survival rates. In view of this advanced treatment
modality we investigated the effects of irradiation with different beam qualities
on gene expression changes in the PC3 prostate adenocarcinoma cell line. For
this purpose, PC3 cells were irradiated with various doses (0.0, 0.5 and 2.0
Gy) of carbon ions (LET=33.7 keV/μm) at the beam of the Grand Accélérateur
National d'Ions Lourds (Caen, France). Comparative experiments with X-rays
were performed at the Belgian Nuclear Research Centre. Genome-wide gene
expression was analyzed using microarrays. Our results show a downregul...
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Abstract. Hadrontherapy is a form of external radiation 
therapy, which uses beams of charged particles such as carbon 
ions. Compared to conventional radiotherapy with photons, 
the main advantage of carbon ion therapy is the precise dose 
localization along with an increased biological effectiveness. 
The first results obtained from prostate cancer patients treated 
with carbon ion therapy showed good local tumor control and 
survival rates. In view of this advanced treatment modality 
we investigated the effects of irradiation with different beam 
qualities on gene expression changes in the PC3 prostate 
adenocarcinoma cell line. For this purpose, PC3 cells were 
irradiated with various doses (0.0, 0.5 and 2.0 Gy) of carbon 
ions (LET=33.7 keV/µm) at the beam of the Grand Accélérateur 
National d'Ions Lourds (Caen, France). Comparative experi-
ments with X-rays were performed at the Belgian Nuclear 
Research Centre. Genome-wide gene expression was analyzed 
using microarrays. Our results show a downregulation in many 
genes involved in cell cycle and cell organization processes 
after 2.0 Gy irradiation. This effect was more pronounced after 
carbon ion irradiation compared with X-rays. Furthermore, 
we found a significant downregulation of many genes related 
to cell motility. Several of these changes were confirmed 
using qPCR. In addition, recurrence-free survival analysis of 
prostate cancer patients based on one of these motility genes 
(FN1) revealed that patients with low expression levels had a 
prolonged recurrence-free survival time, indicating that this 
gene may be a potential prognostic biomarker for prostate 
cancer. Understanding how different radiation qualities affect 
the cellular behavior of prostate cancer cells is important to 
improve the clinical outcome of cancer radiation therapy.
Introduction
Recent advances in radiotherapy, such as hadrontherapy, 
have been added as a radiation treatment choice for specific 
types of cancer. The inverted depth-dose profile and the 
sharp dose fall-off after the Bragg peak offered by charged 
particle beams allow for a more precise localization of the 
radiation dosage to the tumor (1). Due to this greater precision 
the surrounding healthy tissue receives a much lower dose 
compared to conventional radiotherapy with photons. The use 
of carbon ion beams offers, besides this ballistic advantage, 
also a biological advantage. High-linear energy transfer (LET) 
carbon ion radiation has been shown to have a higher rela-
tive biological effectiveness (RBE) compared to conventional 
low-LET photon therapy (2), and is therefore more effective 
in inducing DNA damage, cell cycle arrest and cell death in 
tumor cells (3-5). This accounts for the highly lethal effects 
of carbon ions, even on radioresistant (with respect to X-rays) 
tumors. Currently, carbon ion radiotherapy has been approved 
for treatment of specific types of cancer, including prostate 
cancer (6-8).
Prostate cancer is the second most frequently diagnosed 
cancer and the sixth leading cause of cancer mortality in males 
worldwide (9). Most prostate cancer-related deaths are due to 
metastasis (9-11). So far, first results obtained from prostate 
cancer patients treated with carbon ion therapy, showed good 
local control and high local and biochemical relapse-free 
rates (8,12-15). However, an increased survival rate may be 
accompanied by potential long-term biological consequences 
after carbon ion radiotherapy, including metastasis (16,17).
Metastases occur when cancerous cells acquire properties 
which allow them to detach from the original cancer site and 
adhere to a target organ to form a new tumor (10). Changes 
in gene expression can dysregulate cell signaling pathways, 
thereby leading to changes in functional cell behavior which 
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can ultimately result in cancer metastasis (18,19). Acquiring 
these properties is a multi-step process starting with tumor 
growth, followed by detachment of cancer cells, migration 
and invasion in the surrounding tissue, circulation into blood 
vessels and implantation to a distant organ (20).
Therapeutic intervention may augment the metastatic 
potential of cancer cells, and many authors have suggested 
that a sub-lethal dose of photon irradiation promotes cancer 
cell metastasis by increasing their migration and invasion 
potential (21-27). In particular, Zhou et al (22) irradiated 
cancer cell lines from different organ sites and showed that 
γ-irradiation increased the capacity for migration and inva-
sion, a finding that was also seen in glioblastoma cells (21). 
Interestingly, previous in vitro studies which compared the 
effects of particle and photon beams indicated that particle 
beams can decrease the migration potential of cancer cells 
whereas in most cases X-irradiated samples showed only a 
slight decrease or even an increase in their migration poten-
tial (28-32). Ogata et al (30) irradiated human fibrosarcoma 
cells with X-rays, protons or carbon ion beams and observed a 
dose-dependent decrease in cell migration and invasion caused 
by particle irradiation, whereas low doses of X-rays facilitated 
the process. Goetze et al (28) irradiated glioblastoma cells 
and colorectal carcinoma cells with carbon ions or X-rays and 
found that carbon ion irradiation suppressed the migration 
potential in both cell lines, while X-rays suppressed the migra-
tion potential only in the colon carcinoma cells, indicating a 
cell type-specific effect.
The fate of a cancer cell after radiotherapeutic intervention 
is believed to be controlled by a network of signaling pathways 
that lead to different modes of cell death or survival (33). 
Several studies have compared changes in gene expression of 
cancer cells induced by particle and photon beams (29,34-37). 
Particle beams were found to induce more changes in the 
number of genes that were differently expressed, as well as 
the magnitude of (dose-dependent) gene expression changes. 
Pathways in which these genes were involved were mostly 
related to cell cycle regulation, invasion and angiogenesis 
which may be associated with an enhanced aggressive pheno-
type of the cancer cells. To our knowledge, the effect of carbon 
ion beam radiation on gene expression of prostate cancer cells 
in vitro has not been verified so far.
The main aim of this study was to investigate the impact 
of carbon and X-irradiation on gene expression levels of the 
prostate adenocarcinoma cell line PC3 using whole-genome 
microarrays. This highly invasive cell line exhibits strong 
metastatic activity (38) and is widely used as an in vitro model 
to investigate the biological and cellular responses of human 
prostate cancer cells. Our results demonstrate that carbon ion 
irradiation induced stronger effects at the level of gene expres-
sion compared to similar doses of X-rays. Specifically after 
carbon irradiation, a more pronounced, dose-dependent down-
regulation of genes involved in cell migration and motility was 
observed.
Materials and methods
Cell culture. Human PC3 prostate adenocarcinoma cells were 
obtained from the American Type Culture Collection (ATCC, 
Molsheim, France). They were cultured in F-12K medium 
(ATCC) supplemented with 10% fetal bovine serum (FBS) 
(Gibco, Life Technologies, Ghent, Belgium). Cell cultures were 
maintained in a humidified incubator (37˚C; 5% CO2). For all 
irradiation experiments the same passage number of cells was 
used. For all conditions, we used four separate replicates.
X-irradiation. Cells were plated at a density of 3.5x105 cells 
in 12.5 cm2-tissue culture flasks (Falcon; VWR, Leuven, 
Belgium). After seeding, medium was replaced and cells 
were irradiated in a horizontal position with different doses 
of X-rays (0.0, 0.5 and 2.0 Gy) (Pantak HF420 RX machine; 
250 kV, 15 mA, 1.2 mm Al equivalent and 1 mm Cu-filtered 
X-rays) and a calculated dose rate of 0.25 Gy/min. After irra-
diation, cells were further incubated for 8 h.
Carbon ion irradiation. Cells were plated in 175 cm2-tissue 
culture flasks (Falcon; VWR). Cells were transported by car 
in a transportable incubator at 37˚C to the Grand Accélérateur 
National d'Ions Lourds (GANIL) (Caen, France). During cell 
transportation, culture flasks were completely filled with 
medium. After arrival, medium was replaced and cells were 
placed overnight in a humidified incubator. The following 
day 3.5x105 cells were plated in 12.5 cm2-tissue culture flasks 
(Falcon; VWR). After seeding, the flasks were completely 
filled with medium to allow irradiation in a vertical position. 
Sub-confluent cells were irradiated with a 13C beam with an 
initial energy of 75 MeV/u and a flux of 6.24x105 cm-2sec-1 at the 
D1 beam line at GANIL facility. The dosimetry was performed 
by physicists of CIMAP group at GANIL. It is based on the 
monitoring of the total ion current using the X-ray emission by 
a metallic thin foil inserted in the beam path. For fluxes lower 
than 106 cm-2sec-1, a calibration factor between these secondary 
photons and the particle flux is obtained by counting the ion 
tracks measured on CR39 track detectors. A second step for 
checking the linearity is performed by a conventional ioniza-
tion chamber. Taking into account the different layers before the 
beam arrives at the sample, the resulting LET was 33.7±1.6 keV/
µm, calculated with the SRIM version 2011 code (39). To 
irradiate the samples at 0.0, 0.5 and 2.0 Gy absorbed doses, 
the requested fluences were 0, 9.3x106 cm-2 and 3.7x107 cm-2 by 
using the following equation:
The spot size of the beam was around 4x4 mm2. Immediately 
after irradiation, medium in the flasks was removed (except for 
2 ml) in which the cells were further incubated for 8 h. Control 
samples were treated under similar conditions, including 
transportation and positioning identical to, and simultaneous 
with, that of treated samples.
RNA extraction. Medium was removed from the flasks 8 h 
after irradiation, cells were rinsed with phosphate-buffered 
saline (Gibco) and finally collected in 350 µl RLT buffer 
(Qiagen, Venlo, The Netherlands) with β-mercapto-ethanol 
(Sigma-Aldrich, Bornem, Belgium). Total RNA was isolated 
according to the manufacturer's instructions using AllPrep 
DNA/RNA/protein mini kit (Qiagen). The quantity of 
RNA was measured with the NanoDrop Spectrophotometer 
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(NanoDrop Products, Wilmington, DE, USA) and the 
quality was assessed with an Agilent Bioanalyzer (Agilent 
Technologies, Diegem, Belgium). RNA was stored at -80˚C 
until further processing.
Microarrays and data analysis. Microarrays were prepared 
as reported previously by El-Saghire et al (40). After labeling, 
samples were hybridized onto Human Gene 1.0 ST Array 
Chips (Affymetrix, High Wycombe, UK). Raw data (.cel-files) 
were then imported into Partek software (Partek Genomic 
Suite v5.) (Partek Inc., St. Louis, MO, USA). Quality control 
was performed according to Partek software instructions. 
Based on the PCA of all 24 samples three samples were indi-
cated as outliers and removed from the analysis. To test for 
differential expression two-way ANOVA analysis (with experi-
mental conditions and dose as factors) was performed. P-values 
were adjusted for multiple corrections using false discovery 
rate (FDR) as described by the Benjamini and Hochberg (41) 
procedure. Genes were considered as being differentially 
expressed (DEX) when the fold-change (FC) was 2≤ FC ≤-2 and 
FDR ≤0.05. DEX genes were examined for functional enrich-
ment using the ToppFun tool (http://toppgene.cchmc.org/) 
and applying an FDR corrected P-value of 0.05 for statistical 
significance. Gene Ontology lists of Molecular Function and 
Biological Processes were examined with the visualization 
tool AmiGO (v1.8) available on the Gene Ontology website. 
Further examination of the data set was performed with the 
online tool CateGOrizer in order to get a more precise view 
of the most important affected processes (42). Finally, DEX 
genes were filtered based on the cell motility gene set found 
on the Gene Ontology website (Table I).
Functional enrichment analysis. In order to determine to which 
extent specific gene sets were influenced by changes found in 
genes with Partek software, a gene set enrichment analysis 
(GSEA) was performed. GSEA allows calculating statistically 
significant enrichment of a set of DEX genes towards specific 
pathways or biological processes. Gene ontology databases for 
molecular functions, biological processes and cellular compo-
nents were analyzed separately. Analysis was performed using 
GSEA software (v2.0.10) (43,44). Number of permutations 
was set at 1,000; gene sets were set as permutation type and 
minimum gene set size was 10. Otherwise, default settings 
were maintained. Gene sets were considered to be enriched 
with a FDR P-value ≤0.05. Enrichment maps, which indicate 
relationships between the enriched sets, were visualized for 
gene sets coding for cellular components using the Enrichment 
Map plug-in for the Cytoscape network visualization soft-
ware (45).
cDNA synthesis. cDNA was synthesized with a GoScript™ 
Reverse Transcr ipt ion System (Promega, Leiden, 
The Netherlands) on a GeneAmp PCR System 2700 (Applied 
Biosystems, Foster City, CA, USA). We used 0.4 µg RNA in 
20 µl reactions as per the manufacturer's instructions. cDNA 
samples were stored at -20˚C until further reverse transcriptase 
PCR analysis.
RT-qPCR. Primers for target gene expression analysis (Table II) 
were purchased as pre-made assays (TaqMan Gene Expression 
Assay) (Applied Biosystems). Assays were performed 
according to the manufacturer's instructions. Briefly, 2 µl 
cDNA was added to 1 µl TaqMan Gene expression Primer, 
10 µl TaqMan® Fast Advanced Master Mix and 7 µl RNase 
free water. Assays were run on a 7500 Fast Real-Time PCR 
system (Applied Biosystems). First, efficiency of the primers 
was tested, using a five-step dilution series of an independent 
control sample (Table II). Expression ratios (R) were calculated 
Table I. Cell motility gene set.
Name gene set Website No. of genes No. of genes found No. of significantly
  in set in data set regulated genes
    (after 2.0 Gy C-ion)
GO0048870 - Cell motility Gene Ontology 715 746 50
Table II. The Applied Biosystems assays.
Gene Gene name Assay ID Ref seq Exon Measured 
symbol    boundary efficiency
FN1 Fibronectin 1 Hs01549967_m1 NM_002026.2 3-4 1.98
MYH9 Myosin; heavy chain 9; non-muscle Hs01066369_m1 NM_002473.4 23-24 1.96
NEXN Nexilin Hs00332124_m1 NM_144573.3 10-11 1.91
CCDC88A Coiled-coil domain containing 88A Hs01559766_m1 NM_001135597.1 18-19 1.98
ROCK1 Rho-associated; coiled-coil Hs01127714_mH NM_005406.2 4-5 1.99
 containing protein kinase 1
MYH10 Myosin; heavy chain 10; non-muscle Hs00992050_m1 NM_005964.1 21-22 2.01
B2M β-2-microglobulin Hs00984230_m1 NM_004048.2 3-4 2.05
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using the method as described by Pfaffl (46). Finally, data were 
normalized by a log2 transformation and data are presented as 
average log2(R) ± SD.
Statistical analysis of RT-qPCR. Statistics were performed 
with GraphPad Prism 5.00. Statistical significance of diffe-
rences between log2(R) of control and each experimental 
condition was determined using one-tailed Mann-Whitney 
tests. P-values ≤0.05 were considered statistically significant.
Kaplan-Meier analysis of public patient data. In order to 
assess the clinical relevance of our findings we cross-refe-
renced our results with published patient data. We worked with 
independent, publicly accessible microarray data of prostate 
cancer patients (47,48) which could be imported into Partek. 
Our genes were cross-referenced in the patient data. Data from 
the study of Taylor et al (48) were imported in Partek and 
transformed with a two-base logarithm. Columns with ‘gene 
status’ were inserted, status was appointed as ‘high’ (expres-
sion data more than mean + SD); ‘intermediate’ (expression 
data between the mean + SD and mean - SD); and ‘low’ 
(expression data less than the mean - SD). Data from the study 
of Gulzar et al (47) were imported to Partek. Normal samples 
and duplicates were removed from the set. Properties, such as 
status and time to recurrence, were added to the data. Then, 
the original data were untransformed (anti-log2). Columns 
were filtered based on a list of our genes of interest. Columns 
of ‘gene status’ were inserted, status being appointed as ‘high’ 
(expression data >1.3 vs. reference RNA); ‘intermediate’ 
(expression data ≤1.3 and ≥0.77); and ‘low’ (expression data 
<0.77 vs. reference RNA). When status was appointed data 
were transferred to GraphPad Prism 5.00 for Kaplan-Meier 
analysis based on patient separation in high, intermediate or 
low gene status. Differences in recurrence-free survival were 
considered significant at log-rank P≤0.05.
Ethics statement. All patient data were obtained from 
Taylor et al (48) and Gulzar et al (47) after which they were 
made publicly available. Therefore, their use was not classified 
as human subjects research and no Institutional Review Board 
approval was needed.
Results
Gene expression profiles of PC3 cells were analyzed 8 h after 
exposure to different doses of carbon ion (LET=33.7 keV/µm) 
and X-irradiation. Microarray data analysis followed by GO 
analysis allowed the identification of genes, as well as path-
ways, which were enriched among statistically significant 
genes. Finally our data were cross-referenced with observa-
tions from other studies based on clinical data (47,48).
Principal component analysis (PCA). PCA representing the 
complete gene expression profile presented in two dimensions 
is shown in Fig. 1A. Data indicated similarity between samples, 
whereby shorter distance corresponded with greater simi-
larity. Samples clustered together according to the dose (first 
component) and experimental conditions (second component), 
which described respectively 30.4% and 16.6% of the variance 
within the data when considering all genes. Differences in 
non-irradiated control samples with respect to experimental 
conditions were most likely due to transport of the cells to the 
irradiation facility in France. Low biological variance within 
control samples and samples irradiated with 0.5 Gy resulted in 
distinct clusters for these conditions. Samples irradiated with 
2.0 Gy were more widely distributed over the plot indicating 
increased biological variation after irradiation with this dose. 
PCA also demonstrated a distinct shift in gene expression after 
2.0 vs. 0.0 Gy for both carbon ion and X-irradiation, while only 
a small shift was observed after 0.5 Gy of either beam type.
Differential gene expression after exposure to carbon ion 
irradiation and X-rays. Carbon ion irradiation induced very 
profound effects on gene expression levels. Therefore, very 
strict criteria (-2≥ FC ≥2; FDR ≤0.05) were used in our ana- 
lysis for considering genes as being DEX. We found that 8 h 
Figure 1. Radiation-induced changes in global gene expression. (A) 2D Principal component analysis (PCA) for PC3 cells after various doses of carbon ion 
irradiation or X-rays. PCA is based on global gene expression patterns for each irradiation condition. Analysis revealed distinct clustering in four groups of 
which the percent variability explained by the components dose and experimental conditions was 30.4 and 16.6%, respectively. (B) Venn diagrams showing 
overlap of significantly altered genes after 2.0 Gy irradiation of either beam quality. After 2.0 Gy carbon ion irradiation (white circle) and 2.0 Gy X-rays (grey 
circle) there are respectively 1,663 and 396 genes differentially expressed (DEX). There was a very significant overlap in gene expression changes between 
the conditions.
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after exposure to 2.0 Gy carbon ion irradiation the expression 
of 1,663 genes was changed at least two-fold (Table III). Of 
these, 69% were downregulated and 31% were upregulated. In 
contrast, after 2.0 Gy X-radiation only 396 genes were signifi-
cantly changed. Similar to carbon ion irradiation, the majority 
of the DEX genes after X-ray exposure were downregulated 
(79%). Out of these 396 genes, 360 genes were also DEX after 
exposure to carbon ion irradiation which shows that there was 
a very significant (P≤10-300) overlap in the molecular response 
of PC3 cells to similar doses of high- and low-LET radiation 
(Fig. 1B). Under these strict statistical conditions, no genes 
were significantly changed after exposure to 0.5 Gy of either 
radiation type.
Functional enrichment of the DEX genes after 2.0 Gy 
carbon ion irradiation was examined using the ToppFun tool 
(data not shown). In addition, in order to get a better idea of the 
categories to which the gene sets belong to, the full gene set 
was slimmed with CateGOrizer. For the enriched biological 
processes CateGOrizer identified 21 classes (Fig. 2A), of 
which the majority (19.73%) was involved in cell metabolism. 
Next to this, a high percentage was involved in cell (16.05%) 
and organelle organization (10.64%). In addition, 8.12% of 
the gene sets were involved in cell cycle related processes. 
For the affected molecular functions 16 categories were 
identified (Fig. 2B). Many binding processes were affected 
(20.77% general binding; 17.69% protein binding; 5.38% 
receptor binding; 3.85% cytoskeletal protein binding; 1.54% 
RNA binding; 1.54% nucleic acid binding; 1.54% actin 
binding; 0.77% chromatin binding and 0.77% lipid binding). 
Also various enzymatic activities were influenced by radia-
tion (19.23% catalytic; 10.77% hydrolase; 8.46% transferase 
activity and 3.08% enzyme regulator activity).
Figure 2. Pie chart of the most important (A) biological processes and (B) molecular functions which are affected by 2.0 Gy carbon ion irradiation.
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Functional enrichment analysis. For GSEA, 376, 845 and 
202 gene sets, related to molecular functions (c5.mf.v3.1), 
biological processes (c5bp.v3.1) and cellular components 
(c5.cc.v3.1) respectively, were examined for enrichment among 
the DEX genes. In general, gene sets were mostly enriched 
(upregulated) in the control samples, corresponding with the 
vast amount of genes which are downregulated after irradia-
tion. After 0.5 Gy carbon ion irradiation, 16 gene sets related 
to molecular functions were enriched in the control samples, 
while only one set was enriched in irradiated samples. After 
2.0 Gy carbon ion radiation 57 sets were enriched in the 
controls. For 0.5 Gy X-irradiation no gene sets were found 
to be enriched whereas samples irradiated with 2.0 Gy 
X-rays had 93 enriched sets in control samples compared to 
three enriched gene sets in the irradiated samples. Gene sets 
involved in biological processes (data not shown) were only 
found to be enriched in the control samples. After 2.0 Gy 
X-irradiation 100 enriched gene sets were found. After carbon 
ion irradiation, 31 and 62 gene sets were found to be enriched 
after 0.5 and 2.0 Gy, respectively. Finally, 13 gene sets coding 
for cellular components (data not shown) were enriched in 
samples irradiated with 2.0 Gy carbon ion irradiation, whereas 
for X-rays 11 gene sets were enriched after irradiation with 
2.0 Gy X-rays. Most of these gene sets related to mitochondrial 
structures. In the control samples 17 sets were enriched after 
0.5 Gy carbon ion irradiation. For the X-irradiated samples 
four sets were enriched after 0.5 Gy, while 42 were enriched 
after 2.0 Gy.
In order to get a more comprehensive view of the 
enriched gene sets in different conditions, enrichment maps 
for GO_cellular_components were created with cytoscape 
(Figs. 3 and 4). The figures show that after 0.5 Gy X-irradiation 
no related gene sets coding for cellular components were 
found (Fig. 4). After 0.5 Gy carbon ion irradiation two clus-
ters were identified, which were associated with cytoskeleton 
and chromosomal components. After 2.0 Gy carbon ion or 
X-irradiation a cluster associated with chromosomal compo-
nents were identified, while the cytoskeleton-associated cluster 
included more gene sets compared to 0.5 Gy irradiation, indi-
cating a dose-dependent effect. Additionally, after 2.0 Gy of 
either beam quality two clusters associated with nucleus and 
mitochondrial components were found as well. Finally for the 
2.0 Gy X-irradiation also a cluster associated with extracel-
lular matrix were identified.
Genes involved in cell motility. Given the lack of knowledge of 
potential long-term effects of carbon ion beams, we were in- 
terested in the radiation-induced response of genes related to 
cell migration. Therefore, we filtered the full gene set based 
on a list from the Gene Ontology website (GO0048870 - cell 
motility) containing 715 cell motility related genes. PCA 
revealed a similar spreading of the clusters (Fig. 5A) 
compared to the entire transcriptome (Fig. 1A). However, in 
this case a much larger proportion of the total variance could 
be explained by the dose (74.7%), indicating that the radiation 
dose had a very profound effect on the general expression of 
these genes.
Out of these 746 genes, 50 genes were found to be DEX 
(-2≥ FC ≥2; FDR ≤0.05) after 2.0 Gy carbon ion radiation 
(46 downregulated and 4 upregulated), while only 15 genes 
were changed (all downregulated) after 2.0 Gy X-irradiation 
(Table IV). All of the latter were also significantly regulated 
by 2.0 Gy carbon ion irradiation (Fig. 5B). Unsupervised 
hierarchical clustering of the 50 motility genes that were 
DEX after 2.0 Gy carbon ion irradiation is shown in Fig. 6. A 
clear separation was visible between samples irradiated with 
2.0 Gy (of either beam quality) and non-irradiated or low dose 
(0.5 Gy) irradiated samples. Within this last group two other 
distinct clusters were visible, separating X-ray and carbon ion 
samples.
Six out of these 50 motility genes (NEXN, CCDC88A, 
FN1, MYH9, MYH10 and ROCK1) showed at least a four-fold 
decrease in gene expression after 2.0 Gy carbon ion radiation 
(Table V). Gene expression levels of these six genes were 
found to be two to four times more decreased after 2.0 Gy 
carbon ion radiation compared with 2.0 Gy X-rays. Gene 
expression changes after 0.5 Gy of both radiation types were 
not significantly altered, although a dose-dependent trend in 
expression levels can be seen for both radiation types.
RT-qPCR analysis. Expression levels of NEXN, CCDC88A, 
FN1, MYH9, MYH10 and ROCK1 were validated using 
quantitative real-time PCR. Average log2(R) is presented 
in Fig. 7. For all but one gene the expression levels tended 
to decrease after 0.5 Gy (although not significantly). After 
2.0 Gy the expression of all six genes significantly decreased. 
This effect was more visible in carbon ion irradiated samples 
[log2(R) from -3 to -5] compared to X-irradiation [log2(R) 
from -1.5 to -2.5].
Cross-reference of our results with existing patient data. 
Because of the potential beneficial implications of a down-
regulation of motility-related genes for the prognosis of 
prostate cancer patients, we verified the prognostic power 
of these genes. We used publicly accessible data sets from 
two prostate cancer studies (47,48) to generate Kaplan-Meier 
Table III. Significantly expressed genes: FC ≤-2 or FC ≥2 and FDR ≤0.05.
Radiation Total no. of genes Downregulated Upregulated No. of unidentified genes
0.5 Gy C-ion 0
2.0 Gy C-ion 1663 1145 518 248
0.5 Gy X-ray 0
2.0 Gy X-ray 396 312 84 39
FDR, false discovery rate; FC, fold-change.
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(recurrence-free) survival curves based on differential gene 
expression of our six motility genes (Figs. 8 and 9). Within 
the data set of Taylor et al (48) 150 samples were available for 
analysis for the six genes. Due to missing values in the data 
set of Gulzar et al (47) this data set was limited to 61 samples 
for CCDC88A; 74 for FN1; 60 for NEXN; 79 for MYH9; 77 
for MYH10 and 75 for ROCK1. When samples were stratified 
according to FN1 expression both data sets correlated with 
high gene expression and poor prognosis of the patients (log-
rank P=0.0118 and 0.0257, respectively). This was the only 
gene which was concordantly significant in both data sets. 
High and intermediate levels of CCDC88A correlated with 
a higher overall survival rate (log-rank P=0.0038) within 
the data set of Taylor et al, while analysis of the data set 
of Gulzar et al seemed to show an opposite trend however 
without statistical significance (log-rank P=0.7290). High 
ROCK1 expression correlated with better survival rates (log-
rank P=0.0116) among the patients of Taylor et al, whereas 
within the data set of Gulzar et al an opposite trend could be 
seen. Discrimination based on NEXN expression was highly 
significant within the data set of Taylor et al, however in this 
case low gene expression was associated with poor prognosis 
(log-rank P≤0.0001). This was not the case within the data set 
of Gulzar et al where no statistical discrimination could be 
Figure 3. Enrichment maps based on gene set enrichment analysis (GSEA) for GO cellular components after carbon ion irradiation (A, 0.5 Gy, and B, 
2.0 Gy). White nodes represent gene sets enriched in irradiated samples (i.e. upregulated in irradiated samples), black nodes represent gene sets enriched in 
control samples (i.e. downregulated in irradiated samples). Node size correlates with the number of genes within each gene set. Edge width represents the 
overlap of member genes between gene sets. Enriched gene sets included have a P<0.001 and a false discovery rate (FDR) value P<0.05.
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made (log-rank P=0.2896). MYH9 expression did not show 
any difference in patient survival in the group of Taylor et al. 
However, within the data set of Gulzar et al data appeared to 
show a trend which correlated intermediate-high expression 
of MYH9 with a lower overall survival rate. Therefore, this 
analysis was performed again by dividing patient samples in 
two categories, low and intermediate-high. This resulted in a 
good discrimination between good (low MYH9 expression) and 
poor prognosis (log-rank low vs. intermediate P=0.0079; log-rank 
low vs. intermediate P=0.0073; data not shown). Finally, based 
on MYH10 gene expression patient samples could not discrimi-
nate between good and poor prognosis in either data set.
Table IV. Significantly regulated motility genes: FC ≤-2 or FC ≥2 and FDR ≤0.05.
Radiation Total no. Downregulated genes Upregulated genes
 of genes
0.5 Gy C-ion 0
2.0 Gy C-ion 50 46 4
  ABR, APBB2, APC, ARID5B, BBS1, CCDC88A, CD2AP, DPP4, CXCL3, MIF,
  EGFR, FN1, FYN, GAB2, HOXA5, HOXA7, HOXB9, ICAM1, JMY, PRSS3, S100A2
  L1CAM, LAMC1, MIA3, MYH10, MYH9, NAV1, NDE1, NEXN, NF1,
  NR4A2, NRP2, PIK3CA, PIK3R1, PPARD, PRKCA, PROS1, PROS1,
  PTPRM, RNF20, ROBO1, ROCK1, SOS1, SPAG9, SRGAP1,
  SYNE2, TOP2B, VCAN, VHL, WWC1
0.5 Gy X-ray 0
2.0 Gy X-ray 15 15 0
  CCDC88A, FN1, GAB2, JMY, L1CAM, LAMC1, MIA3, MYH10,
  NEXN, PROS1, PROS1, ROBO1, ROCK1, SYNE2, TOP2B
FDR, false discovery rate; FC, fold-change.
Figure 4. Enrichment Maps based on gene set enrichment analysis (GSEA) for GO cellular components after X-irradiation (A, 0.5 Gy, and B, 2.0 Gy). White 
nodes represent gene sets enriched in irradiated samples (i.e. upregulated in irradiated samples), black nodes represent gene sets in control samples (i.e. 
downregulated in irradiated samples). Node size correlates with the number of genes within each gene set. Edge width represents the overlap of member 
genes between gene sets. Enriched gene sets included have a P<0.001 and a false discovery rate (FDR) value <0.05.
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Figure 5. Radiation-induced changes in motility related gene expression. (A) Principal component analysis (PCA) of motility genes revealed distinct clusters 
similar to global PCA analysis. The percent variability is ~91.5% explained by the components dose (74.7%) and experimental conditions (16.9%). (B) Venn 
diagram showing the overlap of motility genes differentially expressed after 2.0 Gy irradiation. All genes found to be differentially expressed by 2.0 Gy X-rays 
were also regulated by 2.0 Gy carbon ion irradiation.
Figure 6. Heat map of the hierarchical clustering for the 50 motility genes which were significantly regulated by 2.0 Gy carbon ion irradiation. First hierar-
chical separation distinguished samples irradiated with 2.0 Gy on the left of the heat map. Out of the remaining samples, two groups can be distinguished based 
on beam quality [carbon ions (middle) vs. X-ray (right)].
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Discussion
Radiation therapy plays an important role in the management 
of several types of cancer. The fate of an irradiated cancer cell 
is believed to be controlled by a network of signaling pathways 
that lead to different modes of cell death or survival. Although 
most of the cells will die due to the lethal dose, some cells will 
manage to survive after radiotherapeutic intervention, because 
they successfully utilize their repair mechanisms. Numerous 
studies have demonstrated enhanced aggressiveness of surviving 
cancer cells after conventional radiotherapy, accompanied with 
an upregulation of genes that favor cell migration, invasion and 
angiogenesis (21,22,26,49,50). It is well known that carbon ion 
beams have an increased biolo gical effectiveness compared to 
Table V. Microarray data of motility genes selected for RT-qPCR confirmation.
Gene symbol FC 0.5 Gy C-ion FC 2.0 Gy C-iona FC 0.5 Gy X-ray FC 2.0 Gy X-raya
FN1 -1.27 -8.73 -1.03 -2.06
CCDC88A -2.27 -13.87 -1.32 -4.21
ROCK1 -1.57 -11.86 -1.09 -3.27
MYH9 -1.18 -4.46 -1.02 -1.73
NEXN -1.49 -8.36 -1.16 -2.49
MYH10 -1.36 -4.81 -1.15 -2.21
aStatistically significant: FDR P≤0.05. FDR, false discovery rate; FC, fold-change.
Figure 7. Relative gene expression changes of six selected motility genes 8 h after carbon ion or X-irradiation. Log2(ratio) of the expression of (A) MYH9, 
(B) ROCK1, (C) NEXN, (D) FN1, (E) MYH10 and (F) CCDC88A is presented. Significantly altered gene expression compared to CTRL samples (*P≤0.05) 
based on one-tailed Mann-Whitney tests. RT-qPCR results confirm the downregulation observed by microarray analysis after radiation which was more 
pronounced after carbon ion radiation when compared to X-rays.
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X-rays. Therefore, it would not be surprising that both types 
of radiation can induce different effects at the level of gene 
expression. So far, the observed differences in gene expression 
between different radiation qualities are not completely under-
stood. In the present study, we compared the differences in the 
transcriptional response 8 h after carbon ion (LET=33.7 keV/µm) 
and X-irradiation of the human PC3 prostate adenocarcinoma 
cell line. To our knowledge, we are the first to describe global 
gene expression changes after exposure to different radiation 
qualities in prostate cancer cells.
Global radiation-induced gene expression changes. We found 
that 2.0 Gy carbon ion irradiation induced more pronounced 
changes in gene expression compared to similar doses of 
X-rays both in terms of number of genes and magnitude of 
changes. After carbon ion irradiation four times more genes 
were altered in PC3 cells. Our results demonstrated that 
almost 90% of the genes that were significantly altered after 
2.0 Gy X-ray overlapped with those that were changed after 
2.0 Gy carbon ions, indicating that similar molecular pathways 
were affected. Furthermore, 69% of the significantly altered 
genes were downregulated. Under our strict statistical criteria, 
no significant changes were induced after 0.5 Gy irradiation 
for both radiation qualities. Our results are in agreement with 
previous findings of Matsumoto et al (34), who examined gene 
expression in six different melanoma cell lines 1 h and 3 h 
after exposure to X-rays or carbon ion beams (average dose-
LET=50 keV/µm). They found that, after exposure to 2 Gy of 
both radiation types, several hundreds of genes were diffe-
rentially expressed at both time-points. Many of these genes 
showed a greater response to carbon ions compared to X-rays. 
Similar to our results they found that most of the altered genes 
were downregulated after radiation exposure. Higo et al (37) 
irradiated three oral squamous cell carcinoma cell lines with 
X-rays (2, 4 and 8 Gy) and carbon ions (1, 4 and 7 Gy; LET=78 
keV/µm). They also found that carbon ion irradiation induced 
at least a two fold-change in 98 genes for all doses and all 
cell lines of which 85 genes were upregulated and 13 down-
regulated. In agreement with our results, they found more 
genes altered by carbon ion radiation compared to X-rays 
(30 genes upregulated and 4 genes downregulated for all 
doses in all cell lines). However, in contrast with the study 
by Matsumoto et al (34) and our findings most of the genes 
found in the study of Higo et al (37) were upregulated.
Figure 8. Kaplan-Meier survival analysis of (A) CCDC88A, (B) FN1, (C) MYH9, (D) MYH10, (E) NEXN and (F) ROCK1 gene expression performed on the 
data set of Taylor et al (48). Tumor samples were divided into three groups based on whether the gene expression value was high (◆, dark grey); intermediate 
(▲, light grey); or low (●, black). Differences in survival were found to be significant for CCDC88A, FN1, NEXN and ROCK1 when log-rank P≤0.05.
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All these studies observed a greater impact of carbon 
beam irradiation on changes in gene expression compared 
to conventional photon irradiation. However, there are 
differences in the number of genes that are upregulated or 
downregulated. Many factors can be responsible for this 
including the chosen time-point for sample collection. 
Furthermore, differences in cell type, as well as, physical 
aspects including irradiation conditions and LET of the beam 
may have an impact on radiation-induced genome changes.
One limitation of this study is that our results only 
compare equal doses. We are aware that, considering the 
higher RBE of carbon ion beams for a similar dose, carbon 
beams may induce more changes at the gene level compared 
to X-rays. However, because of limited beam time, only a 
small number of experiments could be performed and gene 
expression experiments were selected as first priority over 
an estimation of the RBE. We therefore analyzed radiation-
induced changes in gene expression after equal doses. In 
view of time-dependent fluctuations (29) in gene expression 
induced after irradiation and the difficulty of correlating RBE 
to these time-dependent changes, comparing equal doses for 
gene expression profiling was considered as a suitable alterna-
tive. Indeed Matsumoto et al (34) determined RBE for their 
cell lines and beam qualities but still compared equal doses 
at different time-points. However, future experiments should 
include clonogenic survival assay of PC3 cells exposed to 
carbon ions and X-rays to determine the RBE. Additionally, 
experiments including more doses and more time-points 
would greatly contribute to the characterization of differences 
in carbon ion and X-irradiation.
Radiation-induced signaling pathways. Enrichment analysis 
of the DEX genes indicated that the cell cycle, cellular orga-
nization and metabolism are affected by 2.0 Gy carbon ion 
irradiation. Interestingly, although differential expression after 
0.5 Gy was not found to be significant for single genes, GSEA 
did reveal significant changes.
Also other studies have indicated similar pathways being 
affected by high-LET radiation. Higo et al (37) performed 
Ingenuity Pathway Analysis which indicated significant altera-
tion of several pathways, amongst which the cell cycle, cell 
movement and cell assembly and organization in carbon irra-
diated squamous cell carcinoma. Also Matsumoto et al (34) 
observed many changes in the cell cycle-related genes after 
Figure 9. Kaplan-Meier survival analysis of (A) CCDC88A, (B) FN1, (C) MYH9, (D) MYH10, (E) NEXN and (F) ROCK1 gene expression performed on the 
data set of Gulzar et al (47). Tumor samples were divided into three groups based on whether the gene expression value was high (◆, dark grey); intermediate 
(▲, light grey); or low (●, black). Differences in survival were found to be significant for FN1 (log-rank P=0.0257).
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carbon ion irradiation. In addition, they found that, in four out of 
six cell lines, upregulated genes were mostly p53 target genes. 
In our PC3 cell line, which has a mutated p53 status (51), we 
did not observe many significantly upregulated genes involved 
in the p53 pathway. Matsumoto et al (34) made similar observa-
tions with two of their melanoma cell lines, one of which being 
wild-type, and another having a mutated p53 status. Based 
on their findings, they suggested that downregulation of gene 
expression plays a key role in the extra effect of carbon ions 
compared with X-rays (i.e. an increased radiobiological effec-
tiveness), whereas upregulation of genes relates to sensitivity to 
both beam qualities (i.e. inherent radiosensitivity of the cell to 
radiation).
Cell motility-related gene expression changes. An interesting 
phenomenon observed in in vitro studies is the effect of radia-
tion on cell motility, migration and invasion. Previous studies 
on low-LET photon irradiation already reported an elevated 
migration potential of cancerous cells (21,22,26,49,50). So 
far, however, most studies comparing X-irradiation with 
particle beams indicated that particle radiation attenuates or 
even decreases the migration potential of most cancer cell 
lines (28-32). Therefore, in this study, we more specifically 
focused our gene expression analysis on genes involved in 
cell migration and motility. We observed a dose-dependent 
downregulation after carbon ion irradiation in several genes 
involved in these pathways, which was significant after 2.0 Gy 
radiation. Again, the number and amplitude of gene expression 
changes after X-irradiation of motility related genes was lower 
compared to carbon ion irradiation. For further confirmation 
by RT-qPCR, we focused on six genes of which the expres-
sion was at least four times decreased after 2.0 Gy of carbon 
ion irradiation (CCDC88A, ROCK1, NEXN, FN1, MYH10 
and MYH9). These RT-qPCR results validated the observed 
changes as seen in the microarray analysis.
Fibronectin 1. Downregulation of FN1 gene expression was 
about four times stronger after 2.0 Gy carbon ion irradiation 
compared to 2.0 Gy X-rays, whereas irradiation with a dose 
of 0.5 Gy of either beam quality did not induce a significant 
change. FN1 codes for a glycoprotein and is involved in 
the integrin signaling pathway (52,53), thereby playing an 
important role in tissue organization, cell adhesion and cell 
migration. In addition, fibronectin has been reported to be 
involved in tumor metastasis (54-56). Influence of low-LET 
irradiation on fibronectin expression has been reported previ-
ously by Andarawewa et al (57). They found that human 
mammary epithelial cells exposed to a combination of 2 Gy 
X-ray and TGF-β underwent a morphological shift from an 
epithelial to a mesenchymal phenotype. This shift included 
a higher expression of fibronectin and led to increased cell 
motility and elevated invasion potential of epithelial cells 
in vitro. They suggested that irradiation of these preneoplastic 
cells with moderate doses prime them to undergo epithelial to 
mesenchymal transition (EMT), which could accelerate cancer 
progression. Additionally, Yang et al (58) irradiated a radio-
sensitive and a radioresistant non-small cell lung carcinoma 
cell line with 2 Gy γ-irradiation and analyzed amongst others 
the expression of FN1. Their results indicated that 4 h after 
irradiation gene expression of FN1 was not changed in either 
cell lines. On the other hand, Hei et al (59) found that expo-
sure of immortalized human lung and breast epithelial cells 
to 0.6 Gy high LET α-particles (LET=150 keV/µm) induced 
changes in fibronectin gene expression. Although, northern 
blot analysis could not confirm these results.
So far, different studies observed different effects of radia-
tion on FN1 expression. Whether downregulation of FN1 in 
irradiated PC3 cells will result in changes in cellular behavior 
needs further investigation.
Actin-binding proteins. The other five motility genes (ROCK1, 
CCDC88A, NEXN, MYH9 and MYH10), which we selected 
for further investigation, code for actin-binding proteins. It 
is well known that remodeling of the actin-myosin skeleton 
by activation of the serine/threonine kinase Akt can lead to 
changes in migration, invasion and metastasis (60).
The ROCK1 gene codes for the Rho-associated, coiled 
coil containing protein kinase 1, which is a downstream 
effector of the Rho-pathway, that seems to play a role in 
tumor metastasis and invasion by influencing cell adhesion 
and migration capacity (61,62). Lin et al (62) transfected PC3 
cells with mir-146a, a microRNA found to be downregulated 
in hormone-refractory prostate tumors, which targets ROCK1. 
Suppression of ROCK1 in these prostate cancer cells reduced 
cell proliferation, invasion capacity and their adhesion poten-
tial to bone marrow endothelial cells in vitro. Therefore, it was 
suggested that ROCK1 suppression could aid in reducing the 
metastatic potential of prostate cancer cells. Furthermore, the 
effect of radiation on ROCK1 expression has been previously 
studied. Zhai et al (63) irradiated three glioblastoma cell 
lines with different doses (ranging from 0 to 8 Gy) of photon 
radiation and observed a dose-dependent, enhanced invasive 
potential using in vitro assays. They hypothesized that radi-
ation-induced activation of the PI-3K pathway affected Rho/
ROCK1 signaling. They found that ROCK inhibition signifi-
cantly reduced radiation-induced cellular invasion, whereas 
inhibition of ROCK without radiation exposure had no effect 
on the invasion potential. In a study of Fujita et al (31), pancre-
atic cancer cell lines were irradiated with either carbon ions 
or X-rays. They observed that cancer cells were able to switch 
from a mesenchymal mode of motility to a protease-indepen-
dent mechanism of invasion which was based on actomyosin 
contractility dependent on ROCK signaling. They found that 
although carbon ion radiation was capable of decreasing the 
metastatic potential of these cells, ROCK inhibition was 
needed to block invasiveness. In the present study, we found 
that radiation exposure decreased the expression of ROCK1 
in a dose-dependent way in prostate cancer cells. This effect 
was more pronounced after 2.0 Gy carbon ion irradiation 
compared to 2.0 Gy X-rays, indicating that the magnitude of 
downregulation is radiation quality-dependent. Since previous 
results demonstrated that inhibition of ROCK attenuated 
cell migration capacity, our findings suggest that carbon ion 
irradiation could be more efficient in decreasing the migration 
potential of some cell lines.
One of the functions of ROCK1 is the phosphorylation 
of the myosin light chains. Together with the myosin heavy 
chains (MYH), these proteins are responsible for the motor 
function of the actin-myosin complex, thereby driving various 
motility-based processes such as cytokinesis, cell rounding 
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and cell migration (64). MYH9 and MYH10 genes encode 
for isoforms of non-muscle myosin II heavy chains (65,66). 
MYH9 was reported to be involved in the formation of 
lamellopodia at the leading edge of breast cancer cells (67). 
Furthermore, reducing the expression of MYH9 in an 
invasive form of MCF-7 breast cancer cells blocked the 
invasive potential of these cells (68). Also for CCDC88A 
and NEXN, the involvement of these genes in metastases has 
been described (60,69-71). CCDC88A, also known as GIV or 
Girdin, codes for coiled-coil domain containing 88A, and was 
found to be more highly expressed in samples of colorectal 
cancers with liver metastasis compared to cancers without 
metastasis (60). Garcia-Marcos et al (69) found the full length 
protein exclusively expressed in highly invasive colon, breast 
and pancreatic tumors, suggesting the protein to be a useful 
clinical marker for metastatic potential. Finally, NEXN was 
reported to be involved in cell motility and adhesion of HeLa 
cancer cells through the binding link from actin and the 
plasma membrane (71). To our knowledge no studies specifi-
cally focused on the influence of radiation on the expression 
of genes coding for the actin-binding proteins CCDC88A, 
NEXN, MYH9 and MYH10. However, Fushimi et al (36) 
irradiated oral squamous cell carcinoma cell lines with 
X-rays (2, 4 and 8 Gy), carbon ions or neon ions (1, 4 and 
7 Gy; LET=78 keV/µm) and performed Ingenuity pathway 
analysis. They indicated integrin, actin cytoskeleton and 
PI3K/Akt signaling as affected pathways. The genes found 
in our study also play a role in these motility regulating 
pathways. Additionally, Akino et al (29) found that 12 h after 
irradiation of non-small-cell lung (NSLC) cancer cells with 
5 Gy carbon ions the expression of the actin-binding protein 
anillin (ANLN) was downregulated, while irradiation with 
X-rays increased ANLN expression.
As we mentioned before differences in genes which are 
significantly expressed after irradiation can be due to use of 
other time-points taken for the sampling. Therefore, it could be 
informative to further investigate how the expression of actin-
binding proteins in response to different radiation qualities 
changes during time.
In this study, we found that exposure of prostate cancer 
cells to different radiation qualities decreased the expres-
sion of these five genes coding for actin-binding proteins. 
Furthermore, enrichment analysis indicated that 1.54% of all 
significantly regulated genes are involved in actin-binding 
processes (Fig. 2), and further GSEA analysis indicated 
many gene sets involved in actin-regulation. In view of the 
importance of actin-binding and actin remodeling in migra-
tion processes, it will be important to investigate whether 
this downregulation may lead to changes in cellular behavior, 
thereby influencing the migration potential of the cells. 
Important to mention is that during radiotherapy most of the 
cancer cells will be eliminated because of the lethal dose. 
However, some cells can manage to survive, either because 
they receive sub-lethal doses and/or because they success-
fully induce their repair mechanisms. We are aware that 
in this study, only one time-point was analyzed (8 h) after 
irradiation with a single dose. Further studies could include 
more time-points, as well as fractionated irradiation to get 
a more complete picture of the differences in cell migration 
after low- and high-LET radiation.
Clinically relevant biomarkers in prostate cancer. In view 
of the involvement of these six genes in cancer cell motility 
we also investigated the importance of our selected genes in 
prostate cancer prognoses by performing a recurrence-free 
survival analysis on two independent sets of prostate cancer 
patients (47,48). FN1 was the only gene of which high expres-
sion was significantly correlated with higher recurrence in 
both data sets. This gene has been previously identified as 
a potential biomarker for radiation resistance after genomic 
analysis of several radioresistant head and neck squamous cell 
carcinomas (72). Futhermore, Hébrant et al (70) observed that 
not only FN1 but also CCDC88A and MYH9 were more highly 
expressed in more aggressive anaplastic thyroid carcinomas 
compared to papillary thyroid carcinomas. We observed an 
obvious drop in survival rates in both patient groups with 
high FN1 expression although there was a difference in the 
percentage of recurrence-free survival. However, this may 
be explained by the fact that we took publicly accessible data 
which were processed in a different manner by the original 
authors. We appointed high-intermediate-low gene expression 
based on different criteria in both sets. Adjusting the criteria 
slightly could equalize the difference in survival percentage. 
Performing the same analysis on an even larger study popu-
lation will give more information on how recurrence-free 
survival may be correlated to FN1 gene expression.
Survival analysis was also in agreement for both data sets 
for MYH10 expression and NEXN expression. MYH10 expres-
sion could not be used to distinguish differences in recurrence 
between expression groups, while low NEXN expression corre-
lated with poor survival rates. On the other hand CCDC88A, 
MYH9 and ROCK1 expression predicted a different patient 
outcome in the two study populations. Low MYH9 or ROCK1 
expression tended to be correlated with better recurrence-free 
survival for the patients of Gulzar et al (47), while CCDC88A 
did not distinguish survival between low and high gene expres-
sion groups. However, for the patients of Taylor et al (48) 
low CCDC88A or low ROCK1 expression predicted a poor 
prognosis for the patients and MYH9 expression could not 
distinguish differences in survival based on low or high 
expression. We only found one other study investigating the 
effect of ROCK1 protein expression in osteosarcoma samples 
on patient survival (73). Liu et al correlated high ROCK1 
presence with lower overall survival rates (73). Within our 
analysis both patient groups gave contrary results. Also 
other authors pointed out the difficulties of finding reliable 
prognostic markers within different sets of prostate cancer 
patients (47,48). We conclude that these five actin-binding 
genes may not be suitable biomarkers for prostate cancer 
prognosis, however, our finding that they are downregulated 
after radiation exposure in PC3 cells may lead to changes in 
cell behavior after irradiation.
Although we focused on these five genes in the context 
of cell migration, it should be noted that actin remodeling is 
also a very important process during cell cycle progression 
and mitosis as well. Therefore, it is possible that the observed 
changes are part of, or a side effect of, alterations in cell cycle 
due to radiation exposure rather than an actual change in 
migration potential of the cell. The present study should thus 
be extended with in vitro and in vivo assays to verify whether 
the observed changes are permanent, thereby leading to a 
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change in cellular phenotype or returning to baseline without 
major consequences for the cell. These assays could bring more 
insight into the clinical radiation effects induced in patients.
The main goal of this study was to analyze the effects of 
different types of radiation (carbon ions vs. X-rays) on the 
gene expression of prostate cancer cells. It is well known that 
changes in gene expression play a key role in cancer progres-
sion (18,19).
Dysregulation of signaling pathways in surviving cells after 
radiotherapy, such as those associated with cell migration and 
motility, can determine the fate of the tumor and consequently 
the fate of the patient. Since most prostate cancer-related deaths 
are due to metastases (9-11) it is of pivotal importance to under-
stand how therapeutic intervention can influence metastatic 
development of irradiated cancer cells. Furthermore, cases of 
radiation-induced metastasis in prostate cancer patients have 
been reported (74-77). Since clinical trials, using optimized 
settings for carbon ion treatment, have shown high survival rates 
and good local control (8,12-15), carbon ion irradiation has been 
approved as a valid treatment for prostate cancers (8). However, 
in view of this new treatment option it is of high importance 
to further investigate changes in cancer cells that survived the 
treatment in the context of potential long-term effects.
We found that, under the conditions investigated, carbon 
ion irradiation induced more pronounced changes in PC3 
cells in terms of number of genes and magnitude of changes 
compared to X-rays. We more specifically focused on genes 
involved in cell motility and found that these genes were 
generally downregulated after irradiation, an effect which was 
more pronounced after carbon ion irradiation compared to 
X-rays. This irradiation-induced downregulation may suggest 
a suppressed migration potential of PC3 cells, especially 
after carbon ion irradiation. Further research is needed to 
investigate whether PC3 cells show a decrease in migration 
potential after exposure to different radiation qualities. In this 
regard, functional assays on cell motility and invasion, such as 
the scratch healing assay and Boyden chamber assay can help 
in determining whether the observed changes also influence 
the cellular behavior after irradiation. Understanding how 
different radiation qualities affect the migration potential of 
prostate cancer cells is important for improving the clinical 
outcome of cancer radiation therapy.
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